ABRY Partners LLC
ABRY closes Centauri continuation vehicle and completes Provider Solutions divestiture
Summary: ABRY's official announcement says it closed a $780 million continuation vehicle to extend its partnership with Centauri Health Solutions, with funds managed by Neuberger Private Markets and Apollo S3 serving as co-lead investors. William Blair separately says it advised Centauri Health Solutions and Abry Partners on raising a single-asset continuation fund to acquire Centauri from Abry Fund IX and on the sale of Centauri's Provider Solutions business.
Why it matters: The update may matter to due-diligence readers as a continuation-vehicle and portfolio-company monetization signal for ABRY's healthcare-technology activity, while the sources should not be used to infer fund-level performance, valuation fairness, LP outcomes, or investment merit.
Summary
ABRY’s official announcement says it closed a $780 million continuation vehicle to extend its partnership with Centauri Health Solutions, a healthcare-technology company serving health plans. The ABRY announcement names funds managed by Neuberger Private Markets and Apollo’s Sponsor and Secondary Solutions business as co-lead investors.
William Blair separately says it acted as exclusive financial advisor to Centauri Health Solutions and Abry Partners in connection with raising a single-asset continuation fund to acquire Centauri from Abry Fund IX and with the sale of Centauri’s Provider Solutions business. This draft treats ABRY’s announcement as the controlling source for the continuation-vehicle close and William Blair as the source for the adviser/transaction-process and Provider Solutions divestiture details.
Why it matters
For due-diligence readers, the update is a public signal about ABRY’s use of a continuation vehicle around an existing healthcare-technology portfolio company. Continuation vehicles can be relevant to diligence because they raise questions about sponsor conviction, liquidity choices for existing limited partners, new investor underwriting, governance, and the separation between company performance claims and transaction structure.
The signal is limited. The sources support the announced continuation vehicle, named co-lead investors, William Blair’s advisory role, the Abry Fund IX reference, and the Provider Solutions divestiture. They do not independently establish valuation fairness, LP election outcomes, fund-level returns, ongoing asset quality, Centauri’s future growth, or whether any investor should allocate to or avoid ABRY-related vehicles.
Source notes
- ABRY official announcement: https://abry.com/news-article/abry-partners-closes-780-million-oversubscribed-continuation-vehicle-for-centauri-health-solutions/
- William Blair transaction-adviser page: https://www.williamblair.com/News/Centauri-Health-Solutions-and-Abry-Partners-Transaction
- Pulse 2.0 secondary coverage: https://pulse2.com/abry-partners-closes-780-million-continuation-vehicle-for-centauri-health-solutions/
- Source posture: use ABRY as the primary manager source for the $780 million continuation-vehicle close and co-lead investor wording. Use William Blair for its role as exclusive financial advisor, the Abry Fund IX / single-asset continuation-fund framing, and the Provider Solutions business sale.
- Attribution caveat: omit or tightly attribute company performance, revenue, EBITDA, growth, and value-creation claims. Do not treat those claims as independent validation of transaction economics, company quality, or investment merit.
9AT filing context
Public ADV/private-fund profile context reviewed for this cycle maps the adviser identity to ABRY Partners LLC in Boston, tied to abry.com. The data-context handoff reports approximately $15.0 billion in reported regulatory AUM/profile scale, 4 employees, 4 advisory employees, 36 reported private funds, no separately managed account flag, and a 2026-03-31 ADV submission date.
The same handoff identifies ABRY Partners IX, L.P. as a private equity fund profile with approximately $3.6 billion in gross asset value and 192 owners. That is useful identity/background context because William Blair describes the continuation fund as acquiring Centauri from Abry Fund IX. It should not be used to validate continuation-vehicle economics, valuation process, investor decisions, co-lead investor roles, LP elections, Centauri performance, transaction fairness, or Provider Solutions divestiture terms.
No useful 13F or Form 5500 context is included for this item. The current story is a private-equity continuation-vehicle and portfolio-company transaction update, so public-equity holdings or plan-level context would not add useful source-backed diligence value here.
What to watch
Watch for follow-up ABRY, Centauri, Neuberger, Apollo S3, William Blair, or regulatory/transaction-party disclosures that clarify closing mechanics, governance rights, continuation-vehicle investor composition, Centauri ownership after the transaction, or any additional terms for the Provider Solutions divestiture. Also watch future ABRY healthcare-technology disclosures to distinguish one-off portfolio management from a broader pattern of continuation-vehicle, secondary, or healthcare-platform activity.
Source links
- https://abry.com/news-article/abry-partners-closes-780-million-oversubscribed-continuation-vehicle-for-centauri-health-solutions/
- https://www.williamblair.com/News/Centauri-Health-Solutions-and-Abry-Partners-Transaction
- https://pulse2.com/abry-partners-closes-780-million-continuation-vehicle-for-centauri-health-solutions/